Features
Screener
Pricing
Resources
About
en
Features
Screener
Pricing
Resources
About
Language
en
Login
Start for free
DISCOVER
Screener
Stocks
ETF
Crypto
SCPI
Trending
Comparator
Calendar
Charting
Super investors
SOCIAL
Community
Public portfolios
/
Image Modal
Image Modal Description
Eli Lilly and Company
LLY
-
US5324571083
Compare
Last update : Sep 25, 2026 at 18:25
General
Scores
Financials
Ratios
Valuation
Dividend
Exposure
Analysts
Insider
Eli Lilly and Company (LLY) Business Breakdown and KPIs - Invvest
Settings
Period
5 years
10 years
Max
Customization
Line
Bar
Percentage
Value
Labels
Growth YoY
Sections
Segments
KPIs
Segments
Revenue
Baqsimi Revenue
Jardiance Revenue
Basaglar Revenue
Zepbound Revenue
Humulin Revenue
Cardiovascular Revenue
Others
CAGR
Variation 10 years
Baqsimi Revenue
+3.02%
+34.69%
Jardiance Revenue
+1.18%
+12.45%
Basaglar Revenue
+0.7%
+7.18%
Zepbound Revenue
+2.5%
+27.99%
Humulin Revenue
+0.09%
+0.88%
Cardiovascular Revenue
+1.37%
+14.56%
Others
-0.58%
-5.69%
Revenue by Geography
Other Foreign Countries Revenue
US Revenue
Japan Revenue
Europe Revenue
China Revenue
CAGR
Variation 10 years
Other Foreign Countries Revenue
-0.23%
-2.29%
US Revenue
+1.28%
+13.57%
Japan Revenue
+1.6%
+17.24%
Europe Revenue
-2%
-18.3%
China Revenue
-3.7%
-31.42%
KPIs
Revenue Change due to Price
Revenue Change due to Price
CAGR
Variation 10 years
Revenue Change due to Price
-2.36%
-21.27%
Revenue Change due to Volume
Revenue Change due to Volume
CAGR
Variation 10 years
Revenue Change due to Volume
+2.77%
+31.4%
Revenue Change due to FX
Revenue Change due to FX
CAGR
Variation 10 years
Revenue Change due to FX
-2.05%
-18.71%
